ANAB vs TRAX
ANAB: AnaptysBio is a streamlined royalty management company focused on maximizing the value of long-term financial collaborations for therapeutic antibodies like Jemperli. TRAX: A clinical-stage biotechnology company developing novel antibody therapies to treat autoimmune and inflammatory conditions.
Side-by-side fundamentals
| Metric | ANAB | TRAX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $46.21 | $32.01 | |
| Market cap | $1.3B | $1.1B | |
| Net margin FY2025, SEC XBRL | -5.6% | n/a | |
| Operating margin FY2025, SEC XBRL | +20.4% | n/a | |
| ROE FY2025, SEC XBRL | -35.6% | n/a | |
| ROA FY2025, SEC XBRL | -3.6% | n/a | |
| Debt / equity as of 2026-09-03 | 20.69 | 0.00 | TRAX lower |
| Revenue growth (YoY) as of 2026-09-03 | +107.7% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +183.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.73 | 1.40 | |
| 1-year return as of 2026-10-08 close | +117.8% | n/a |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.